Daptomycin-Induced Posterior Reversible Encephalopathy Syndrome (PRES)

Clicks: 415
ID: 7995
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #1 of 16 articles by views in case reports in neurological medicine

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Aims. To present a 60-year-old female patient who manifested clinical and radiological features of posterior reversible encephalopathy syndrome (PRES) following the administration of Daptomycin for glycopeptide-resistant Enterococcal urinary tract infection. Material. Case report. Method. Posterior reversible encephalopathy syndrome was diagnosed in our patient following the administration of Daptomycin based on clinical suspicion as well as brain CT and MRI imaging. Results. The temporal association between the initiation of Daptomycin and the onset of PRES is highly suggestive of causality, and this is further supported by clinical and radiological resolution after Daptomycin was withdrawn. Conclusion. This is the first report of Daptomycin-induced posterior reversible encephalopathy syndrome.
Reference Key
a2019daptomycininducedcase Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bitar De Zayas-Enriquez, A.;Soper, C.;Bitar De Zayas-Enriquez, A.;Soper, C.;
Journal case reports in neurological medicine
Year 2019
DOI
10.1155/2019/8756932
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.